[2]
Rezaei N,Moazzami K,Aghamohammadi A,Klein C, Neutropenia and primary immunodeficiency diseases. International reviews of immunology. 2009
[PubMed PMID: 19811314]
[3]
Bohn G,Welte K,Klein C, Severe congenital neutropenia: new genes explain an old disease. Current opinion in rheumatology. 2007 Nov
[PubMed PMID: 17917547]
Level 3 (low-level) evidence
[4]
Accelerated phase of chediak higashi syndrome mimicking lymphoma--a case report., Nargund AR,Madhumathi DS,Premalatha CS,Rao CR,Appaji L,Lakshmidevi V,, Journal of pediatric hematology/oncology, 2010 Aug
[PubMed PMID: 20661157]
Level 3 (low-level) evidence
[5]
Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences., Hsieh MM,Everhart JE,Byrd-Holt DD,Tisdale JF,Rodgers GP,, Annals of internal medicine, 2007 Apr 3
[PubMed PMID: 17404350]
[6]
Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings., Weycker D,Barron R,Kartashov A,Legg J,Lyman GH,, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014 Jun
[PubMed PMID: 23824496]
[7]
Jolis L,Carabantes F,Pernas S,Cantos B,López A,Torres P,Funes C,Caballero D,Benedit P,Salar A,PRAXIS Study Group., Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. European journal of cancer care. 2013 Jul
[PubMed PMID: 23730920]
Level 2 (mid-level) evidence
[8]
Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease., Rider NL,Jameson MB,Creech CB,, Journal of the Pediatric Infectious Diseases Society, 2018 May 9
[PubMed PMID: 29746675]
[9]
Möttönen M,Lanning M,Baumann P,Saarinen-Pihkala UM, Chediak-Higashi syndrome: four cases from Northern Finland. Acta paediatrica (Oslo, Norway : 1992). 2003 Sep
[PubMed PMID: 14599068]
Level 3 (low-level) evidence
[10]
Khoo AL,Zhao YJ,Teng M,Ying D,Jin J,Chee YL,Poon LM,Lim SE,Koh LP,Chng WJ,Lim BP,Hsu LY,Chai LYA, Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia. International journal of antimicrobial agents. 2018 Sep
[PubMed PMID: 29751120]
[11]
Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism., Dotta L,Parolini S,Prandini A,Tabellini G,Antolini M,Kingsmore SF,Badolato R,, Orphanet journal of rare diseases, 2013 Oct 17
[PubMed PMID: 24134793]
[12]
Clinical manifestations and outcomes of pediatric chronic neutropenia., Wan C,Yu HH,Lu MY,Lee JH,Wang LC,Lin YT,Yang YH,Chiang BL,, Journal of the Formosan Medical Association = Taiwan yi zhi, 2012 Apr
[PubMed PMID: 22526211]
[13]
Slack MA,Thomsen IP, Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease. Journal of the Pediatric Infectious Diseases Society. 2018 May 9
[PubMed PMID: 29746681]
[14]
Al-Herz W,Nanda A, Skin manifestations in primary immunodeficient children. Pediatric dermatology. 2011 Sep-Oct
[PubMed PMID: 21453308]
[15]
Zermatten MG,Koenig C,von Allmen A,Agyeman P,Ammann RA, Episodes of fever in neutropenia in pediatric patients with cancer in Bern, Switzerland, 1993-2012. Scientific data. 2019 Jan 15
[PubMed PMID: 30644854]
[16]
Wuyts L,Wojciechowski M,Maes P,Matthieu L,Lambert J,Aerts O, Juvenile ecthyma gangrenosum caused by Pseudomonas aeruginosa revealing an underlying neutropenia: case report and review of the literature. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 Jan 11;
[PubMed PMID: 30633375]
Level 3 (low-level) evidence
[17]
Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment., Pilatova K,Bencsikova B,Demlova R,Valik D,Zdrazilova-Dubska L,, Cancer immunology, immunotherapy : CII, 2018 May 10
[PubMed PMID: 29748897]
[18]
Perparim K,Hashimoto A,Nasu M, Efficacy of recombinant human granulocyte-colony stimulating factor alone and in combination with antifungal agents against disseminated trichosporonosis in neutropenic mice. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 1996
[PubMed PMID: 29681373]
[19]
Connelly JA,Marsh R,Parikh S,Talano JA, Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art. Journal of the Pediatric Infectious Diseases Society. 2018 May 9
[PubMed PMID: 29746680]
[21]
Afzali P,Isaeian A,Sadeghi P,Moazzami B,Parvaneh N,Robatjazi M,Ziaee V, Complement deficiency in pediatric-onset systemic lupus erythematosus. Journal of laboratory physicians. 2018 Apr-Jun;
[PubMed PMID: 29692593]
[22]
García de Guadiana-Romualdo L,Cerezuela-Fuentes P,Español-Morales I,Esteban-Torrella P,Jiménez-Santos E,Hernando-Holgado A,Albaladejo-Otón MD, Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department. Biochemia medica. 2019 Feb 15;
[PubMed PMID: 30591812]
[23]
Islam LN,Nabi AH,Rahman MM,Khan MA,Kazi AI, Association of clinical complications with nutritional status and the prevalence of leukopenia among arsenic patients in Bangladesh. International journal of environmental research and public health. 2004 Sep;
[PubMed PMID: 16696181]
[24]
Johannsen CF,Petersen TS,Nielsen J,Jørgensen A,Jimenez-Solem E,Fink-Jensen A, Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study. Therapeutic advances in psychopharmacology. 2022;
[PubMed PMID: 35273789]
Level 2 (mid-level) evidence